FDA's new view on peptide compounding could change industry practices.
Concerns over safety led to the initial ban on injectable peptides.
Ongoing war in Iran is impacting trial recruitment efforts.
Strategic angle: The FDA is reconsidering its stance on compounding pharmacies, potentially allowing the production of injectable peptides previously banned due to safety concerns.
FDA's new view on peptide compounding could change industry practices.
Concerns over safety led to the initial ban on injectable peptides.
Ongoing war in Iran is impacting trial recruitment efforts.